Global pharmaceutical company Allergan has announced that a technology developed at LSU Health New Orleans, Anterios, is part of its latest acquisition deal. Created by Drs. Ann Tilton, Dana Suskind and Mary Caire, the Anterios technology is used to treat or prevent acne.
Anterios, a clinical stage pharmaceutical company, licensed an LSU Health-patented technology in 2008. LSU Health formerly held equity in the company.
Allergan is based in Dublin and known as makers of best-known brands of botulinum toxin, BOTOX® and BOTOX® Cosmetic.
The company will pay Anterios $90 million now plus potential development and commercial milestone payments. LSU Health New Orleans will receive a pro rata share of the upfront consideration in the Anterios transaction, explained the release, plus a pro rata share of any of the contingent consideration if and when the milestones are reached.
“The acquisition of Anterios by Allergan further validates the model of universities working with small companies to commercialize inventions,” said Patrick E. Reed, MS, RTTP, Director of the LSU Health New Orleans Office of Technology Management.
Anterios shareholders have now spun out the company and created Eirion Therapeutics, which LSU Health has received stock in.